Summary

• 30-year experience in biologic drug discovery and development.
• 50 issued US patents related to antibody/protein therapeutics and technologies.
• 117 peer reviewed publications.
• Was responsible for AstraZeneca’s and MedImmune’s global biologic drug discovery and technology including antibody discovery, antibody/protein engineering, antibody-drug conjugates, bi-specifics/multi-specifics, therapeutic peptides, protein scaffolds, protein sciences, proteomics/metabolomics, structural biology, in vivo expressed biologics (AAV gene therapy, cell therapy and RNA/DNA therapy), and production cell line generation.
• Played a key role in building AstraZeneca’s and MedImmune’s biologics pipeline for cancers, respiratory diseases, autoimmune diseases, inflammation, cardiovascular and metabolic diseases, infectious diseases and CNS/pain. His work had led to 8 FDA approved biologics:
  • anti-PD-L1 antibody (Imfinzi®; durvalumab) for cancer.
  • anti-IL-5α receptor antibody (Fasenra®; benralizumab) for eosinophilic asthma.
  • anti-CD22 immunotoxin (LumoxitiTM; moxetumomab pasudotox) for hairy cell leukaemia.
  • anti-CD19 antibody (Uplizna™; inebilizumab-cdon) for neuromyelitis optica spectrum disorder.
  • anti-type I interferon receptor antibody (Saphnelo™, anifrolumab) for systemic lupus erythematosus
  • Evusheld™ (tixagevimab and cilgavimab), long-acting antibody combination for COVID-19.
  • anti-IL-13 antibody (Adbry™; tralokinumab) for atopic dermatitis.
  • Beyfortus® (nirsevimab), a single dose long-acting anti-RSV antibody for RSV lower respiratory tract disease.
• In addition to the 8 market approved antibodies, he had helped build hundreds of biologic programs in research and development with >80 programs advanced into clinical development.